Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Gain Therapeutics ( (GANX) ) has shared an update.
Gain Therapeutics has received approval in Australia to commence a Phase 1b clinical trial for GT-02287, aimed at treating Parkinson’s disease. This trial will assess safety, tolerability, and biomarkers, following a successful Phase 1 study in healthy volunteers. The Phase 1b trial is a significant step forward for Gain Therapeutics, marking their transition into clinical-stage development and aligning with their goal to progress GT-02287 into further phases. The trial’s outcomes are anticipated to be a critical milestone in mid-2025, potentially enhancing the company’s position in the biotechnology industry.
More about Gain Therapeutics
Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing next-generation allosteric small molecule therapies. The company’s lead drug candidate, GT-02287, is being developed for the treatment of Parkinson’s disease, with or without a GBA1 mutation, and is part of their broader efforts to tackle neurodegenerative diseases and other complex disorders using their advanced Magellan™ platform.
YTD Price Performance: -52.15%
Average Trading Volume: 311,961
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $41.38M
For a thorough assessment of GANX stock, go to TipRanks’ Stock Analysis page.
